Trial NCT02358538 investigated ganaxolone as an anti-epileptic drug in Cyclin dependent kinase like 5 (CDKL5), Lennox-Gastaut syndrome, and Protocadherin 19 (PCDH19) patients and reported % Reduction from Baseline in Seizure Frequency as mean (SD) -49.20 (50.2), -37.75 (7.89) and -19.95 (63.57), respectively. The gene discussed is CDKL5; the disease is Seizure.